To Get more Insights,  Request A Free Sample 

Demand Defining Factors Analysis 

Robotics and Outpatient Surgery are Defining the New Standard of Care

A profound operational shift is redefining the hip replacement market, with procedures increasingly migrating to outpatient settings powered by robotic technology. A key catalyst for this move, as reported by the Centers for Medicare & Medicaid Services (CMS), was the addition of 11 new surgical codes to the Ambulatory Surgery Center list in 2024. Consequently, major operators are expanding rapidly. For instance, Surgery Partners reported a massive increase in total joint replacements in Q3 2024, while USPI added 11 new ASCs in Q2 2024, including three high-volume centers that handle over 15,000 cases annually.

This transition is enabled by robotic platforms offering sub-millimeter accuracy, which enhances surgical precision. Leading this charge in the hip replacement market, Stryker announced its Mako system has been used in over 2 million procedures globally. The widespread adoption of these technologies is clear, with Intuitive Surgical reporting over 1.8 million da Vinci procedures annually across its installed base of more than 8,000 systems worldwide. To accommodate this growth, major ASC operators like USPI and Surgical Care Affiliates managed approximately 520 and 320 centers respectively in 2024. The total number of Medicare-certified ASCs has now reached approximately 6,000, creating a robust infrastructure for this new standard of care.

Evolving Patient Needs and Advanced Materials are Fueling Implant Innovation

Demand within the hip replacement market is also being shaped by an evolving patient demographic and a revolution in material science. The leading cause of hip failure, osteoarthritis, is a significant factor, with a 2024 analysis published in The Lancet estimating that 595 million people are living with the condition globally. In the U.S., the CDC reports that 58.5 million adults have some form of arthritis. Critically, this is not just a condition of the elderly; a growing number of hip replacements are now being performed on individuals younger than 65, who have higher expectations for implant longevity and performance.

To meet the needs of these younger, more active patients, implant technology is advancing at a rapid pace. The use of 3D printing for creating customized implants is becoming a key solution in the hip replacement market for solving complex primary hip replacement cases. For example, surgeons are now using custom 3D-printed joints to rebuild a patient’s pelvis after significant bone loss. In addition, advanced materials are extending implant longevity. A major 2025 clinical study on Vitamin E-infused polyethylene liners revealed significantly lower wear rates at the 10-year mark. The real-world impact is clear, as one 2024 report showed a revision incidence of just 2.3% for these advanced liners. Such innovations are vital, especially since infection remains a primary concern, accounting for 26.3% of all revision surgeries in 2023.

 Segmental Analysis 

Unwavering Patient Trust Solidifies Total Hip Replacement's Premier Position

Total hip replacement surgery unquestionably stands as the leading procedure within the broader hip replacement market, a dominance supported by a remarkable volume of successful operations. For instance, the American Joint Replacement Registry's 2024 report analyzed over 4.3 million procedures, revealing that primary total hip arthroplasty (THA) represented a substantial 32.4% of these surgeries in 2023. This preference is also reflected in surgical practice, where the average surgeon undertook 44.3 elective primary THAs that year. Consequently, a high demand creates significant logistical challenges for healthcare systems.

Despite an 18% surge in hip replacement procedures in Canada hip replacement market between 2019 and 2023, only 66% of patients were able to receive their surgery within the recommended 26-week window. This backlog highlights the sustained and growing need for this life-enhancing procedure. Furthermore, the waiting lists tell a compelling story; in early 2025, some Canadian patients faced an average wait of 30.3 weeks. The situation in Ireland is similar, with 105 patients at one major orthopedic hospital waiting 6-12 months as of September 2024. While some studies show hemiarthroplasty has lower readmission rates for specific geriatric fracture cases, the comprehensive benefits of a total hip replacement cement its status as the preferred long-term solution.

• In 2023, the workload for an average surgeon involved performing nearly one primary total hip replacement per week.
• A multinational study found that the need for a second surgery within two years was nearly identical for both total and partial hip replacements.
• The longest-waiting 10% of patients in some parts of Canada faced a wait time of approximately 44.4 weeks for their procedure in early 2025.

Proven Durability Cements Metal-on-Polyethylene's Leadership in Hip Implants

Within the dynamic hip replacement market, the metal-on-polyethylene combination remains the material of choice, a leadership position justified by its market penetration and proven clinical performance. In 2024, these bearings impressively captured 46.53% of all hip replacement sales, signaling strong trust from surgeons and healthcare providers. While ceramic-on-polyethylene has become the most common bearing for elective primary procedures, constituting 73.5% of cases in 2023, the enduring legacy and cost-effectiveness of metal heads on highly cross-linked polyethylene (HXLPE) ensure its continued relevance.

The exceptional durability of HXLPE is a primary reason for its widespread use across the global hip replacement market. A 2025 study focused on younger patients under 30 revealed a low volumetric wear rate of about 20.8 mm³/yr, demonstrating its resilience against the high demands of more active individuals. Further reinforcing this, a ten-year analysis of a third-generation HXLPE liner showed an even lower mean linear wear rate of just 0.0172 mm/year. The long-term success of any hip replacement hinges on such material innovations. Specific implant trials confirm these findings, with one randomized study showing a wear rate of just 0.01 mm/yr for a 28-mm metal-on-XLPE articulation, solidifying its reputation for longevity.

• Despite the rise of ceramics, metal-on-polyethylene continues to hold nearly half of the market share for implant materials.
• Even in the most active young patients, first-generation advanced polyethylene demonstrates a wear rate measured in tiny fractions of a millimeter per year.
• A long-term study following a specific cross-linked polyethylene liner for over a decade recorded an average wear of only 0.03 mm annually.

Hospitals Remain the Cornerstone of Hip Replacement Surgical Care Delivery

Hospitals continue to be the dominant end-user in the hip replacement market, serving as the central hub for the vast majority of surgical procedures and post-operative care. In 2024, an overwhelming 71.42% of all hip replacement surgeries were performed in a hospital setting. The United States alone has approximately 6,093 hospitals, with Newsweek recognizing 175 of them in 2025 for their excellence in orthopedics. Moreover, hospitals have become remarkably efficient; the average length of stay for a primary total hip arthroplasty in the U.S. was a brief 1.1 days in 2023, with a striking 92% of patients being discharged directly to their homes.

While hospitals firmly hold their leading position, the hip replacement market is witnessing a notable evolution with the expansion of Ambulatory Surgery Centers (ASCs). The number of ASCs equipped to perform total hip arthroplasty increased by 34% in 2023 alone. By the end of that year, these outpatient centers reported performing 62,110 total joint procedures, marking a 70% increase from 2022. Nevertheless, hospitals are indispensable for managing complex cases and post-surgical complications. For example, readmission rates within three months stood at 8% at one major Irish university hospital in 2021, and another study noted readmission rates near 6.9% for patients discharged to specialized care facilities after their hip replacement.

• In 2023, more than nine out of every ten primary hip replacement patients in the U.S. went straight home from the hospital.
• The volume of joint replacements performed in outpatient surgery centers experienced a dramatic 70% jump in a single year.
• A comprehensive study found that over 81% of patients were discharged from the hospital within two weeks of their surgery.

 Regional Analysis 

North America's Dominance Is Fueled by Technology and High Surgical Volumes

North America commands the hip replacement market with a formidable 41.33% share, driven by high procedural volumes and rapid technological adoption in the United States. In 2024, the American Academy of Orthopaedic Surgeons reported over 35,000 members, forming a vast network of specialists. The U.S. is projected to perform 652,000 total hip arthroplasties in 2025 alone. A major hospital system, HCA Healthcare, performed 58,000 inpatient joint replacement procedures in 2024. The infrastructure supporting this volume is extensive; there are approximately 6,000 Medicare-certified Ambulatory Surgery Centers active in 2024. In Canada, the Canadian Institute for Health Information reported over 65,000 hip replacement surgeries were performed last year.

The region's leadership in the hip replacement market is also cemented by its embrace of advanced technology. In the U.S., there are more than 2,500 orthopedic medical device companies driving innovation. The installed base of robotic systems is growing, with over 1,500 Mako systems in the U.S. as of early 2024. However, access remains a challenge in some areas. For instance, in 2024, the median wait time for a hip replacement in Ontario, Canada, was 190 days. This demand is further underscored by the high incidence of related injuries, with the CDC reporting over 300,000 older adults hospitalized for hip fractures annually in the U.S.

Europe’s Established Registries and Healthcare Systems Drive Steady Market Demand

Europe’s mature hip replacement market is characterized by robust national healthcare systems and comprehensive joint registries that ensure high standards of care. In the UK, the National Health Service (NHS) performs over 100,000 hip replacement operations annually. The UK’s National Joint Registry, a critical resource, contained records of over 1.6 million primary hip replacement procedures by 2024. Germany also demonstrates high surgical volumes, with approximately 240,000 hip replacement procedures performed each year. In Sweden, the Swedish Hip Arthroplasty Register has tracked nearly 2 million procedures since its inception.

Despite high volumes, patient access can be strained. In England, the NHS waiting list for trauma and orthopedic treatment included over 800,000 patients in early 2024. The regional hip replacement market’s surgical workforce is substantial; Germany has over 8,000 orthopedic and trauma surgeons. To improve care, France has more than 1,400 public hospitals equipped for major surgeries. The region also faces a significant burden from osteoporosis-related fractures, with over 500,000 such incidents reported in Germany in 2024. In the Netherlands, there are 110 hospitals performing joint replacements.

Asia Pacific Emerges as the Fastest Growing Hip Replacement Market Hub

The Asia Pacific region is rapidly becoming a center for growth in the hip replacement market, propelled by expanding healthcare infrastructure and a growing elderly population. Australia showcases a highly developed market, with its National Joint Replacement Registry reporting over 52,000 hip replacement procedures in its latest annual report. Japan’s super-aged society, with over 36 million people aged 65 and older in 2024, creates a substantial patient base. The Japanese Orthopaedic Association has over 25,000 members serving this population. In India, the number of orthopedic surgeons has surpassed 20,000.

The region's growth in the global hip replacement market is supported by a burgeoning medical device industry and investment in specialized facilities. China now has over 2,000 domestic orthopedic implant manufacturers. India has seen the development of over 200 dedicated orthopedic specialty hospitals to meet rising demand. Furthermore, the number of robotic surgical systems in China exceeded 360 units in early 2024. Medical tourism is also a factor, with countries like Thailand performing thousands of joint replacements for international patients annually. In South Korea, the National Health Insurance Service covers over 30,000 hip replacement procedures per year.

Recent Developments in Hip Replacement Market 

• Enovis Finalizes Transformative Acquisition of LimaCorporate S.p.A.: This move significantly expands the global reach and reconstructive portfolio of Enovis, boosting its international presence.
• Stryker Completes Acquisition of French Joint Replacement Leader SERF SAS: The deal strengthens Stryker's joint replacement offerings and footprint across Europe, particularly in the French market.
• Zimmer Biomet Acquires Commercial Assets from OSSIS for Patient-Specific Implants: This acquisition enhances ZB's capabilities in providing 3D-printed, patient-specific implants to the Asia Pacific region.
• CurvaFix Secures USD 39 Million in New Financing for Fracture Repair System: These funds will accelerate the U.S. commercialization of its unique, patented system for repairing pelvic fractures.
• OrthoPediatrics Corp. Acquires Boston Orthotics & Prosthetics for USD 22 Million: This acquisition in the hip replacement market expands the company's specialty bracing portfolio and broadens its reach into the pediatric orthotics market.
• Bioventus Completes Acquisition of CartiHeal for Cartilage Regeneration Tech: This deal adds a novel cartilage and bone regeneration device for knee injuries to the Bioventus portfolio.
• Zimmer Biomet enters into agreement to distribute Think Surgical's Robotic Business: This strategic move bolsters the company’s robotic surgery offerings with a focus on hip and knee replacement systems.

Top Companies in the Hip Replacement Market

• Arthrex
• B. Braun SE
• Bioimpianti
• Conformis
• Corin Group
• Enovis (DJO Global)
• Exactech Inc.
• Globus Medical
• Integra LifeSciences
• Johnson & Johnson (DePuy Synthes)
• JRI Orthopaedics
• LimaCorporate
• Mathys Ltd Bettlach
• Medacta Group
• MicroPort Scientific Corporation
• Smith & Nephew plc
• Stryker Corporation
• United Orthopedic
• Wright Medical Group N.V.
• Zimmer Biomet
• Other Prominent Players

Market Segmentation Overview

By Procedure

• Primary hip reconstruction devices
  • Cemented primary hip reconstruction surgeries
  • Cementless primary hip reconstruction surgeries
• Partial hip reconstruction surgeries
  • Cemented partial hip
  • Cementless partial hip
• Hip resurfacing surgeries
• Revision hip reconstruction
• Total replacement

By Material

• Metal-on-metal
• Metal-on-polyethylene
• Ceramic-on-polyethylene
• Ceramic-on-metal
• Ceramic-on-ceramic

By End User

• Hospitals
• Speciality Clinics
• Ambulatory Surgery Centres

By Region

• North America
  • The US
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia and New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America